XML 48 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900

Summary of Significant Accounting Policies - Collaborative Research and Licensing Agreements - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue recognition
Total	$ 2,584,300								$ 2,584,300
Revenue recognized	21,754	$ 3,503	$ 1,014	$ 1,491	$ 5,664	$ 848	$ 824	$ 2,184	27,762	$ 9,520	$ 10,172
Accounts receivable	44				2,966				44	2,966
Deferred revenue	33,800				$ 4,600				33,800	4,600
Development-based
Revenue recognition
Total	406,300								406,300
Regulatory-based
Revenue recognition
Total	767,000								767,000
Sales-based
Revenue recognition
Total	1,411,000								1,411,000
UNITED STATES
Revenue recognition
Revenue recognized									22,400	8,600	4,200
Non United States
Revenue recognition
Revenue recognized									5,400	900	6,000
Amgen, Inc.
Revenue recognition
Total	1,657,500								1,657,500
Revenue recognized									13,800	6,900	2,200
Deferred revenue	0								0
Amgen, Inc. | Development-based
Revenue recognition
Total	232,500								232,500
Amgen, Inc. | Regulatory-based
Revenue recognition
Total	345,000								345,000
Amgen, Inc. | Sales-based
Revenue recognition
Total	1,080,000								1,080,000
MorphoSys
Revenue recognition
Total	299,000								299,000
Revenue recognized									8,500	1,000	900
MorphoSys | Development-based
Revenue recognition
Total	62,000								62,000
MorphoSys | Regulatory-based
Revenue recognition
Total	187,000								187,000
MorphoSys | Sales-based
Revenue recognition
Total	50,000								50,000
Alexion Pharmaceuticals, Inc.
Revenue recognition
Total	399,000								399,000
Revenue recognized									2,500	700	2,900
Alexion Pharmaceuticals, Inc. | Development-based
Revenue recognition
Total	51,000								51,000
Alexion Pharmaceuticals, Inc. | Regulatory-based
Revenue recognition
Total	168,000								168,000
Alexion Pharmaceuticals, Inc. | Sales-based
Revenue recognition
Total	180,000								180,000
BI
Revenue recognition
Total	27,000								27,000
BI | Development-based
Revenue recognition
Total	9,000								9,000
BI | Regulatory-based
Revenue recognition
Total	6,000								6,000
BI | Sales-based
Revenue recognition
Total	12,000								12,000
CSL Limited
Revenue recognition
Revenue recognized											3,000
Janssen
Revenue recognition
Total	10,000								10,000
Janssen | Development-based
Revenue recognition
Total	6,000								6,000
Janssen | Sales-based
Revenue recognition
Total	4,000								4,000
Merck Sharp & Dohme Corp.
Revenue recognition
Total	9,500								9,500
Revenue recognized									2,900
Merck Sharp & Dohme Corp. | Development-based
Revenue recognition
Total	3,500								3,500
Merck Sharp & Dohme Corp. | Regulatory-based
Revenue recognition
Total	6,000								6,000
Novo Nordisk
Revenue recognition
Total	167,300								167,300
Revenue recognized									100	600	1,000
Novo Nordisk | Development-based
Revenue recognition
Total	36,300								36,300
Novo Nordisk | Regulatory-based
Revenue recognition
Total	51,000								51,000
Novo Nordisk | Sales-based
Revenue recognition
Total	80,000								80,000
Other
Revenue recognition
Revenue recognized										300	200
2009 Research License and Commercialization Agreement | CSL Limited
Revenue recognition
Total	15,000								15,000
Revenue recognized									2,500	$ 700	2,400
Deferred revenue	0								0
2009 Research License and Commercialization Agreement | CSL Limited | Development-based
Revenue recognition
Total	6,000								6,000
2009 Research License and Commercialization Agreement | CSL Limited | Regulatory-based
Revenue recognition
Total	4,000								4,000
2009 Research License and Commercialization Agreement | CSL Limited | Sales-based
Revenue recognition
Total	5,000								5,000
May 2013 Research License and Commercialization Agreement | CSL Limited
Revenue recognition
Revenue recognized											$ 500
Deferred revenue	$ 0								$ 0

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3-4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a(1)
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the revenue earned during the period pertaining to collaborations, licenses and milestones.

+ References

No definition available.

+ Details

Name:	xncr_CollaborationsLicensesAndMilestonesRevenue
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties.

+ References

No definition available.

+ Details

Name:	xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix:	xncr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=xncr_NonUnitedStatesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_BIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_CSLLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_JanssenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_MerckSharpAndDohmeCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_NovoNordiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=xncr_OtherCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndCommercialization2009AgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=xncr_May2013ResearchLicenseAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: